Labelling Solutions Adding Speed & Precision In Drug Delivery

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...
- Advertisement -

In recent years, there has been an increasing awareness of the importance when it comes to acting quickly and also being adaptable when it comes to the development and delivery of pharmaceutical products. The expedited trials for the COVID-19 jabs also highlighted the vitality of being proactive and working in tandem throughout the entire supply chain. The onset of the pandemic has led regulatory authorities, pharma companies, research institutions, as well as manufacturers to partner in ways that were not explored before. The medical trials were simplified, making sure that safety and scientific measures that were strict got maintained.

The pandemic has stressed on the significance of maintaining communication as well as valid information flow throughout the pharmaceutical supply chain. Every aspect of the supply chain, be it from raw material suppliers to manufacturers and distribution networks, had to rapidly adjust to meet the high demand for the COVID-19 vaccine rollout. The pandemic actually paced up the progress of trends that were already taking place in the pharmaceutical industry, especially when it comes to the adoption of important digital techniques such as cloud computing. 

The significance of a drug’s packaging and label is often not given its due, despite being vital for the seamless transportation of any product. Cloud-based labelling solutions happen to be essential for providing important delivery details, levelling up visibility, making sure that compliance is there along with regulations, and lessening the risk of recalls that are expensive. In the pharmaceutical landscape, making sure of patient wellbeing as well as treatment efficacy happen to be the top priorities. Because of this, packaging and labelling happen to play a crucial role in protecting both handlers and, of course, the end consumers.

Navigating an intricate regulatory landscape

The precision as well as clarity of pharmaceutical products get significant attention, as they both are rightfully crucial. The pharmaceutical industry, which already has some extensive regulations in place, has recently undergone numerous changes globally. These are the European Union’s execution of the False Medicines Directive, Brazil’s adoption of the National Medicine Control System, as well as the FDA’s updated Code of Federal Regulation.

In the coming years, the industry must anticipate additional regulations. The US Drug Supply Chain Security Act, which is designed to establish an electronic traceable supply chain to safeguard the infiltration of counterfeit and fraudulent medication, is all set to be implemented in November 2023. The European Parliament has given its nod for an extension of the implementation of the European Union’s Medical Device Regulation. The regulation will now be implemented in all possible ways in 2027. Manufacturers often go on to find themselves stressed by the ever-altering regulations, which can result in elevated risks as well as costs. According to a recent report titled ‘2023 Top 5 Trends in Labelling and Packaging Artwork’, it does not come as a surprise that 84% of business leaders find demand regulations of today to be more intricate than ever before.

The label goes on to play a significant role for pharmaceutical companies, as they are supposed to be complying with both current as well as future regulations. Pharmaceutical companies can effectively make sure to manage as well as update labels, partner with stakeholders, and at the same time access real-time information from anywhere and that too at any time by making sure to execute a centralised cloud-based labelling solution. This improvement not only elevates the speed, precision, as well as efficiency of drug delivery and also packaging processes, but also goes on to provide manufacturers with data that is essential and is also required to comply with numerous regulations across different jurisdictions. Cloud-based systems offer a range of benefits for manufacturers. These happen to include real-time monitoring, advanced safety precautions, scalability that is easy, and better collaboration capabilities. By ensuring to utilise these features, manufacturers can streamline and, at the same time, automate their processes, allowing them to devote more attention to their core operations.

The importance of traceability cannot be overstated. Traceability is a crucial aspect in various industries, including food production, manufacturing, and supply chain management. It refers to the

Traceability- Its Significance

Visibility happens to be imperative throughout the supply chain, especially in the pharmaceutical industry, where the stakes happen to be high. With recent technological advancements, it is now much easier to track products both upstream as well as downstream. The label serves as a crucial component in connecting the digital and physical aspects of the product by providing essential data ranging from serial numbers and certificate origins to batch details. The label essentially allows for a complete audit trail that traces the journey of raw ingredients across manufacturing and distribution, all the way to the end-user. This helps in eradicating counterfeit drugs from the supply chain, goes on to make sure of patient safety, and protects the image of the brand.

Pharmaceutical companies can make sure to elevate their label management by making use of cloud technology. This approach offers many benefits, including the likes of improved quality control, upgraded risk mitigation, and safeguarding against unnecessary recalls that are caused due to label and print errors. 

Pharmaceutical Manufacturing: Future Proofing

The response of the pharmaceutical sector to recent challenges highlights the crucial significance of speed, partnership, as well as adherence to regulations that keep changing. The rapid creation of the COVID-19 vaccine has laid the importance of efficient communication and embracing of the supply chain. Cloud-based labelling solutions have come up as a crucial aspect of improving processes and making sure of compliance. The integration of this technology ensures not just regulatory compliance but also makes efficiency, patient safety, and brand reputation more robust. So as to navigate the intricate regulatory landscape, it is important for the industry to embrace innovative solutions like cloud-based labelling. This will help pharmaceutical companies to establish a strong path towards a secure as well as effective future.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Billerud Introduces New Pharmaceutical Packaging Option

Billerud has officially introduced PharmaKraft, a specialized fibre-based packaging...

AstraZeneca Advances AI Drug Discovery Deal with insitro

AstraZeneca has inked a billion-dollar AI drug discovery partnership...

Managing Quality and Regulatory Risks in Pharmaceutical Technology Transfer

Technology transfer moves more than manufacturing instructions. It moves process knowledge, supplier dependencies, labeling requirements, packaging specifications, and the evidence needed to demonstrate control. For medical device manufacturers, including those supporting drug-device combination products, these interfaces can become recurring sources of compliance gaps during site transitions, acquisitions, and remediation. The central problem is often not a missing procedure. It is a quality system that allows connected activities to change independently. A label revision may be approved while packaging artwork, supplier instructions, or production-system data still reflect an obsolete version. Staying inspection-ready requires manufacturers to manage these dependencies as one controlled system. Why Compliance Gaps Keep Recurring Findings are treated as documentation defects Revising a procedure can resolve an immediate discrepancy without changing the behavior that caused it. If unclear decision rights, weak escalation, or ineffective training remain, the same failure may surface elsewhere. Corrective and preventive action should distinguish the observed finding from its underlying cause and establish how effectiveness will be demonstrated. Ownership is divided across connected functions Quality, Regulatory Affairs, labeling, packaging engineering, operations, suppliers, and digital-system owners often maintain separate workflows. Each team may complete its assigned task while an interface remains uncontrolled. For example, changing an instruction for use can affect packaging configuration, translations, technical documentation, inventory disposition, and release controls. Transitions expose unresolved weaknesses Acquisitions and site transfers can introduce conflicting procedures, incomplete knowledge transfer, or different assumptions about validated processes. Regulatory changes add further demands. When these events coincide with CAPA or change-control backlogs, teams may prioritize administrative closure over risk reduction. Without a coordinated impact assessment, local fixes can create new gaps downstream. Establish the Regulatory Baseline Inspection readiness starts with knowing which requirements apply to the product, activity, and market. Pharmaceutical, device, and combination-product obligations are not interchangeable; transfer planning should identify the applicable requirements rather than assume one quality framework covers every operation. According to FDA’s Quality Management System Regulation overview and FAQs, the QMSR became effective on February 2, 2026, incorporates ISO 13485:2016 by reference, and introduced the updated device inspection process under Compliance Program 7382.850. ISO 13485 certification does not exempt a manufacturer from FDA inspection or guarantee compliance with FDA requirements. For devices marketed in the European Union, Regulation (EU) 2017/745, Annex I, Section 23, provides the primary requirements for information supplied with devices, including labels and instructions for use. Teams should assess the applicable provisions alongside relevant language, product-specific, and market requirements. A labeling review should therefore evaluate required content and consistency with the device’s intended purpose and supporting documentation—not merely artwork accuracy. How to Identify the Real Gaps Begin with a cross-functional assessment that follows actual product and information flows. Select representative transfers, label changes, supplier changes, and CAPAs, then trace each from initiation through implementation and effectiveness review. Map dependencies: Identify affected specifications, suppliers, packaging components, systems, validation activities, and training. Compare records with practice: Check whether approved procedures match what operators and reviewers actually do. Test traceability: Follow a requirement through technical documentation, labeling, production instructions, and release evidence. Examine recurrence: Look for repeated deviations, reopened actions, overdue changes, and findings shared across sites. Assess capacity: Determine whether qualified owners have enough time and authority to complete corrective work. Prioritize gaps by potential patient or user harm, regulatory impact, likelihood of recurrence, and detectability. Document the rationale; an old overdue item is not automatically more important than a newly identified high-risk weakness. Align Quality, Labeling, Packaging, and Change Control Create a coordinated remediation plan with one accountable owner for each action, named contributors, acceptance criteria, and required evidence. Separate immediate containment from systemic correction. Containment might prevent obsolete labels from being issued; correction might redesign approval and implementation controls so obsolete versions cannot return. Use change control as the integration point. Before approval, evaluate effects on regulatory submissions or notifications, technical documentation, supplier controls, packaging performance, validation, electronic master data, inventory, and training. Record both identified impacts and justified decisions that particular activities are unaffected. During technology transfer, define readiness gates before production or release responsibilities move. These should address the transfer of process knowledge, acceptance criteria, receiving-site capability, required qualification or validation, approved documents, and personnel competence. The appropriate evidence depends on the product and process; a generic checklist cannot replace a documented assessment. Finally, verify implementation where the work happens. Confirm that current instructions are available, suppliers received approved requirements, systems contain correct versions, and affected personnel can perform their tasks. A signed approval is not evidence that every downstream change took effect. Mistakes That Undermine Inspection Readiness Closing CAPAs on task completion alone: Effectiveness checks should test whether the underlying failure has been controlled. Updating labels in isolation: Assess packaging, supplier, system, documentation, and inventory consequences. Counting closures instead of evidence: Dashboards need defensible records behind their status indicators. ...

State of API & Peptide CDMO Capacity

Pharmaceutical companies planning peptide or complex small-molecule launches are...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »